

TABLE 1. "BIG 4" DRUGS & ANNUAL SALES			
DRUG	CONDITION	COMPANY	ANNUAL \$B
Ritalin Dexedrine Quillivant	ADHD	GSK-Pfizer	<u>24</u> Total ADHD Market projected (2024)
Epi-pen (Currently in Court for Anti-trust/fraud)	Anaphylaxis Asthma	Pfizer/Mylan (formerly Merck)	<u>BILLIONS</u>
Advair (Seretide)	Asthma	GSK	<u>4.36</u> (2017)
Ventolin Albuterol	Asthma-Inhaler	GSK	<u>1.13</u> (2014)
Flovent	Asthma	GSK	<u>1.39</u> (2014)
Singulair	Asthma	Merck	<u>4.87</u> (2010)
Remicade	Autoimmune	Merck- J&J	<u>7.16</u> (2017)
Enbrel	Autoimmune Rheumatoid Arthritis	Pfizer-Amgen	<u>7.98</u> (2017)
Celebrex	Autoimmune	Pfizer	<u>2.1</u> (2013)
Xeljanz	Autoimmune	Pfizer	<u>1</u> (2017)
Lyrica	Epilepsy	Pfizer	<u>4.51</u> (2017)
Neurontin	Seizures/ Epilepsy	Pfizer	<u>1.7</u> (2001)